Haemonetics Corporation (HAE) Stock Analysis
Recovery setup
Healthcare · Medical Devices
Sell if holding. Momentum 2.7/10 is below the 5.0 floor at $59.58 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Customer: limited number of customers; Concentration risk — Supplier: single vendor.
Haemonetics is a global medical technology company serving plasma collection, blood centers, and hospitals with devices, disposables, and software. Its ten largest customers account for approximately 42% of net revenues; the Plasma segment revenue is concentrated among a limited... Read more
Sell if holding. Momentum 2.7/10 is below the 5.0 floor at $59.58 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Customer: limited number of customers; Concentration risk — Supplier: single vendor. Chart setup: Death cross but MACD improving, RSI 58. Score 5.8/10, moderate confidence.
Passes 4/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, semi cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA) and earnings proximity 7d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHCustomerlimited number of customers10-K Item 1A: 'a material portion of sales in our Plasma segment come from (and we anticipate will continue to come from) a limited number of customers.'
- HIGHSuppliersingle vendor10-K Item 1A: 'Currently, we rely on a single vendor to support several of our business processes, including customer service and support and elements of enterprise technology'
- HIGHSupplierTetakawi10-K Item 1A: 'We are reliant on Tetakawi to provide these services...could significantly harm our ability to manufacture our vascular closure devices'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 2.7/10 is below the 5.0 floor at $59.58 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Customer: limited number of customers; Concentration risk — Supplier: single vendor. Chart setup: Death cross but MACD improving, RSI 58. Prior stop was $55.61. Score 5.8/10, moderate confidence.
Take-profit target: $73.60 (+23.6% upside). Prior stop was $55.61. Stop-loss: $55.61.
Concentration risk — Customer: limited number of customers; Concentration risk — Supplier: single vendor; Leverage penalty (D/E 1.3): -0.5.
Haemonetics Corporation trades at a P/E of 16.3 (forward 11.2). TrendMatrix value score: 7.8/10. Verdict: Sell.
15 analysts cover HAE with a consensus score of 3.9/5. Average price target: $85.
What does Haemonetics Corporation do?Haemonetics is a global medical technology company serving plasma collection, blood centers, and hospitals with...
Haemonetics is a global medical technology company serving plasma collection, blood centers, and hospitals with devices, disposables, and software. Its ten largest customers account for approximately 42% of net revenues; the Plasma segment revenue is concentrated among a limited number of customers. A market-and-regional alignment restructuring launched in early FY2026 to redirect resources toward highest-growth markets.